Compare First Trust Cloud Computing ETF (SKYY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs Sanofi SA — how do they compare? First Trust Cloud Computing ETF trades at $175.32 (market cap $3.47B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 27.4× First Trust Cloud Computing ETF's market cap, and Sanofi SA pays a 6.01% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and Sanofi SA for 94 Days on average.
| SKYY | SNY | |
|---|---|---|
Market Cap | $3.47B | $95.18B |
Volume | 176,159 | 2,995,646 |
52-Week High | $171.01 | $52.34 |
52-Week Low | $104.16 | $39.51 |
Typical Hold Time | 85 Days | 94 Days |
Sector | — | Health |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY (First Trust Cloud Computing ETF) trades at $174.885, up 2.4% with strong bullish technical signals from moving averages. The ETF recently hit a 52-week high, benefiting from AI-driven cloud computing demand. Technical indicators show bullish momentum with support at $169 and resistance at $171. The fund provides diversified exposure to cloud infrastructure and software companies without heavy concentration in mega-cap tech stocks.
The outlook remains positive as cloud computing benefits from secular trends including AI adoption and digital transformation. Key risks include sector concentration and market volatility. Institutional activity shows mixed sentiment with some firms trimming positions while broader analyst coverage highlights the ETF's strategic positioning in the growing cloud computing market.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
